Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HPV Positive Oropharyngeal Squamous Cell Carcinoma: early-phase trial registry
10 of 17 indexed HPV Positive Oropharyngeal Squamous Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 10 currently recruiting · #1,004 of 28,707 conditions by registered trial count
HPV Positive Oropharyngeal Squamous Cell Carcinoma: 17 US clinical trials tracked, 10 recruiting.
HPV Positive Oropharyngeal Squamous Cell Carcinoma is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is PDS Biotechnology, running 2 of these trials.
Enrollment posture brief
Registry condition hpv-positive-oropharyngeal-squamous-cell-carcinoma
OPEN 10 | RECR 59% | LATE 1 | EARLY 12 | RANK #1004 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Nephrolithiasis (59% recruiting · 17 trials)
HPV Positive Oropharyngeal Squamous Cell Carcinoma lists 10 open slots (59% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HPV Positive Oropharyngeal Squamous Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HPV Positive Oropharyngeal Squamous Cell Carcinoma is recruiting above its size-band peers.
10 of 17 indexed trials (58.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of HPV Positive Oropharyngeal Squamous Cell Carcinoma trials is spread across many organizations.
PDS Biotechnology accounts for 2 of 17 trials (11.8%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most HPV Positive Oropharyngeal Squamous Cell Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 83 among the 17 trials that report a genuine target (sentinel values excluded). 12 of those (70.6%) plan for fewer than 100 participants.
-
HPV Positive Oropharyngeal Squamous Cell Carcinoma research is mostly interventional.
14 interventional and 3 observational studies make up this index (82.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study
Jonathan Schoenfeld, MD, MPH
NCT04900623
Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma
NYU Langone Health
NCT03215719
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
University of California, Irvine
NCT05600842
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
University of Chicago
NCT05108870
The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)
Icahn School of Medicine at Mount Sinai
NCT05419089
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
Theravectys S.A.
NCT06319963
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
University of Maryland, Baltimore
NCT06088381
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
Memorial Sloan Kettering Cancer Center
NCT05307939
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
University of Missouri-Columbia
NCT04444869
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Christian Hinrichs
NCT05639972
Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
PDS Biotechnology
NCT06790966
Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma
Indiana University
NCT05119036
Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer
Cedars-Sinai Medical Center
NCT04502407
A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)
Memorial Sloan Kettering Cancer Center
NCT05814549
ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)
Massachusetts Eye and Ear Infirmary
NCT06730412
Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC
PDS Biotechnology
NCT04260126
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
Dana-Farber Cancer Institute
NCT02113878
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 8 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on HPV Positive Oropharyngeal Squamous Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HPV Positive Oropharyngeal Squamous Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HPV Positive Oropharyngeal Squamous Cell Carcinoma page
17 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 HPV Positive Oropharyngeal Squamous Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- PDS Biotechnology sponsors the most HPV Positive Oropharyngeal Squamous Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See PDS Biotechnology's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HPV Positive Oropharyngeal Squamous Cell Carcinoma condition card totals 17 registered trials; most-linked intervention Pembrolizumab (KEYTRUDA®) and PDS0101; top US site state New Jersey. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.